Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01300949 · ClinicalTrials.gov registry record · NA
Spaeth/Richman Contrast Sensitivity Test
A NA study, sponsored by Wills Eye.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
NCT01300949 is a NA study that has completed, run by Wills Eye. The registered enrollment target is 314 participants.
The verdict
NCT01300949, a NA study, has completed, sponsored by Wills Eye.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
Study Summary
The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test, another way to measure vision, is performed on any standard computer with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson contrast test.
Interventions
- DIAGNOSTIC_TEST Spaeth/Richman Contrast Sensitivity Test
- DIAGNOSTIC_TEST Pelli-Robson Contrast Sensitivity Chart
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01300949
The ClinicalTrials.gov registry entry for NCT01300949 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wills Eye, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Spaeth/Richman Contrast Sensitivity Test is the first listed.
NCT01300949 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01300949 about?
NCT01300949 is a clinical study titled "Spaeth/Richman Contrast Sensitivity Test". The Spaeth-Richman Contrast Sensitivity (SPARCS) test is a new method of assessing contrast sensitivity. The test, another way to measure vision, is performed on any standard computer with internet access. Patients will be tested with SPARCS and with the standard Pelli-Robson contrast test.
What is the current status of trial NCT01300949?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2010-01. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01300949?
The interventions under investigation include: Spaeth/Richman Contrast Sensitivity Test (DIAGNOSTIC_TEST), Pelli-Robson Contrast Sensitivity Chart (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT01300949?
This trial is sponsored by Wills Eye, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.